Caxton Associates (UK)’s Integra LifeSciences IART Stock Holding History

Caxton Associates (UK)’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$361K	Buy	+22,177	New	+$383K	0.01%	533

Other funds holding IART

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Paradigm Capital Management Inc Albany, New York $3.17B AUM 63.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $33.9B AUM 47.7% 1-Year Est. Return

Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

Caxton Associates (UK)'s IART Position: Q3 2026 in Review

Caxton Associates (UK) opened a new position in Integra LifeSciences (IART) in Q3 2026: 22,177 shares worth $361K. The stake represents 0.01% of the portfolio and ranks #533 among its holdings.

179 funds tracked by Wall St. Rank hold IART as of Q3 2026.

Caxton Associates (UK) held 22,177 shares of Integra LifeSciences worth $361K as of Q3 2026.
Integra LifeSciences was a new Caxton Associates (UK) position in Q3 2026.
Integra LifeSciences made up 0.01% of Caxton Associates (UK)'s portfolio in Q3 2026, its #533 holding.
179 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2026.

Based on Caxton Associates (UK)'s 13F filing for Q3 2026, filed 13 Nov 2026.